A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
← catalyst calendarNCT06034002 · readout in 802 d
Sponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
290estimated
Sites
13
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-12-04 | actual | When the study began enrolling |
| Primary completion | 2028-10-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-10-29 | estimated | The whole study's end, after follow-up |
| First posted | 2023-09-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Myeloproliferative Neoplasms
Interventions
- Drug: INCA033989
- Drug: Ruxolitinib — also filed as Jakafi
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with Dose Limiting Toxicities (DLTs)
measured Up to 28 days
Number of participants with Treatment-emergent Adverse Events (TEAEs)
measured Up to 3 years and 60 days
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed